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Abstract
Background: Suicide and major depressive disorders (MDD) are strongly associated, and genetic factors are
responsible for at least part of the variability in suicide risk. We investigated whether variation at the tryptophan
hydroxylase-2 (TPH2) gene rs7305115 SNP may predispose to suicide attempts in MDD.
Methods: We genotyped TPH2 gene rs7305115 SNP in 215 MDD patients with suicide and matched MDD patients
without suicide. Differences in behavioral and personality traits according to genotypic variation were investigated
by logistic regression analysis.
Results: There were no significant differences between MDD patients with suicide and controls in genotypic (AG
and GG) frequencies for rs7305115 SNP, but the distribution of AA genotype differed significantly (14.4% vs. 29.3%,
p < 0.001). The G-allele frequency was significantly higher in cases than control group (58.1% vs.45.6%, p < 0.001),
but the A-allele carrier indicated a decreased trend in MDD with suicide behaviors than control group (41.9%
vs.54.4%, p < 0.001). The multivariate logistic regression analysis indicated that TPH2 rs7305115 AA (OR 0.33, 95% CI
0.22-0.99), family history of suicide (OR 2.98, 95% CI 1.17-5.04), negative life events half year ago (OR 6.64, 95% CI
2.48-11.04) and hopelessness (OR 7.68, 95% CI 5.79-13.74) were significantly associated with the suicide behaviors in
MDD patients.
Conclusions: The study suggested that hopelessness, negative life events and family history of suicide were risk
factors of attempted suicide in MDD while the TPH2 rs7305115A remained a significant protective predictor of
suicide attempts.
Background
Suicide is an important public health problem and ranks
a m o n gt h et o p1 0c a u s e so fd e a t hf o ri n d i v i d u a l so fa l l
ages and major depressive disorders (MDD) appeared to
confer greater risk for suicide [1,2]. Suicidal behavior is
commonly considered to result from an interaction of
genetic, neurobiological, and psychosocial factors.
Genetic risk factors are estimated to account for
approximately 30% to 40% of the variance in suicidal
behavior, however the precise mechanism of the genetic
contribution are unknown [3].
Dysregulation of brain serotonin contributes to many
psychiatric disorders. Furthermore, abnormal serotoner-
gic function has frequently been reported in individuals
who commit or attempt suicide and is one of the most
replicated findings in modern biological psychiatry [4].
For example, low levels of serotonin (5-hydroxytrypta-
mine, 5-HT) have also been observed in suicide victims
and 5-HT could play a role in the predisposition to sui-
cide [5]. Tryptophan hydroxylase (TPH), the rate limiting
enzyme in the biosynthesis of 5-HT neurotransmission,
is a major candidate for genetic association studies in
many psychiatric disorders, including suicide [6,7]. Two
genes coding TPH (TPH1 and TPH2) have been differen-
tiated. The human TPH2 gene is located on chromosome
12q15, comprises 11 exons, and covers a region of about
93.5 kilobases (gene accession number: NM_173353).
TPH2, rather than TPH1, is preferentially expressed in
the brain [8]. TPH2 is neuron-specific and expressed pre-
dominantly in serotonergic neurons of the raphe nuclei
and in the peripheral myenteric neurons in the gut
[9,10]. The genetic polymorphisms affecting TPH2 gene
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any medium, provided the original work is properly cited.expression might result in the alteration of physiological
processes related to 5-HT. 5-HT is involved in the dys-
function of numerous psychiatric disorders and beha-
vioral traits, such as MDD, suicide, or depression.
To date, nearly five hundred SNPs have been identi-
fied in human TPH2, most of them located in non-
coding regions of the gene. However, a few functional
polymorphisms have been reported. A functional
(C1473G) SNP in mouse TPH2 that results in the sub-
stitution of Pro447 with Arg447 and leads to decreased
serotonin levels in PC12 cells provides direct evidence
for TPH2 controls brain serotonin synthesis [11]. Zill
et al provides evidence for an involvement of genetic
variants of the TPH2 gene in the pathogenesis of
MDD and might be a hint on the repeatedly discussed
duality of the serotonergic system [12]. The human
TPH2 promoter polymorphism rs11178997 impacts on
TPH2 expression, which might have implications for
the development and function of the serotonergic sys-
t e mi nt h eb r a i n[ 1 3 ] .T h eT P H 2g e n ea n di t s5 ’
upstream region variants (SNPs: rs4448731 and
rs4641527) may be involved in the predisposition to
suicide in MDD [14]. The core promoter of human
TPH2 was localized to the region between -107 and
+7, and the segment of +8 to +53 within the 5’-UTR
was found to exert a potent inhibitory effect on gene
expression at both transcriptional and post-transcrip-
tional levels [15]. The TPH2 C2755A polymorphism
may represent a population-specific risk factor for
peripartum major depression and anxiety disorder, per-
haps by interacting with hormones in Chinese [16].
These results may open up new research strategies for
the analysis of the observed disturbances in the seroto-
nergic system in patients suffering from several other
psychiatric disorders. Understanding the mechanisms
of TPH2 gene polymorphism in suicide attempters
may shed light on the neurobiology of the vulnerability
to suicidal behavior and reveal potential targets of pre-
ventive and therapeutic actions.
In the current study, we investigated another TPH2
polymorphism named rs7305115 at approximately
1077 bp from the 7 exon. To our knowledge, its func-
tionality has not been studied so far. Therefore, the
purpose of the present study was to detect possible
association between rs7305115 polymorphisms of
TPH2 gene and suicide behavior in MDD patients. We
performed association and linkage disequilibrium stu-
dies on 215 MDD who committed suicide and 215
control MDD patients without suicide behavior. It
could be an attempt to examine the association
between different components-genetic, environmental,
neurobiological, and behavioral of a complex, multi-
variate and heterogeneous phenomenon.
Materials and methods
Patients and controls
The sample investigated consisted of 430 unrelated
MDD patients who were recruited from Mar 2004 to
May 2008 in the Han nationality of Shandong Province,
China. All patients (184 males, 246 females) hospitalized
in psychiatric clinics in Shandong, China. Diagnosis of
MDD should be confirmed by the Mini International
Neuropsychiatric Interview and by a minimum score of
Hamilton Depression Rating Scale (HDRS) [17,18]. All
cases met DSM-IV diagnostic criteria for MDD and
were severe enough to require follow-up in a specialized
psychiatric outpatient clinic [19,20]. Axis I and Axis II
psychopathologies were determined using the Structured
Clinical Interview for DSM-IV Axis I Disorders (SCID-I)
and the Structured Clinical Interview for DSM-IV Per-
sonality Disorders (SCID-II), respectively. The SCID was
administered to all patient subjects by experienced psy-
chiatrists. By means of structured questionnaires, infor-
mation on specific demographic and clinical variables,
such as family history of suicide and history of physical
or sexual abuse, was also obtained.
Two hundred and fifteen MDD patients (defined as
MDD+suicide group, 92 males, and 123 females) conse-
cutively admitted to our psychiatric departments after a
suicide were included in this study. The suicide patient
was defined as intentional self-harm to end one’s life
but not die as a result of his/her action(s). Individuals
were scored as positive for a history of suicide attempt
only when medical records documented a severe
attempt, a relative or partner con- firmed the history, or
there was physical evidence confirming the history. We
classified suicide methods as violent or nonviolent
according to the classification used in previous study
[21]. Drug overdose, carbon monoxide poisoning, and
drowning were considered nonviolent. All other meth-
ods were classified as violent.
Two hundred and fifteen MDD control patients
(defined as MDD-suicide group, 92 males, and 123
females) without suicide attempt, which were closely
matched with individual patients in the suicidal group
in terms of age and gender, were selected for this study.
They met all the DSM-IV criteria for major depressive
disorder and had HDRS scored of over 18. They had no
previous history of suicide attempt or family history of
suicide. The other exclusion criteria included evidence
of alcohol or drug dependency, significant organic brain
disease, and clinically significant somatic disease.
All cases and control subjects were the Han popula-
tion and came from the same geographical area in east-
ern China. The protocol of the study was in accordance
with the ethics standards of the committee on Human
Experimentation of Nanjing Medical University.
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Venous blood was drawn and immediately frozen in ali-
quots at -70°C or below until analyzed. For genotyping,
genomic DNA was extracted from EDTA blood samples
by using a commercial DNA extract kit, Wizard Geno-
mic DNA purification kit (Promega, Madison, WI,
USA). TPH2 rs7305115 SNP genotyping was performed
by DNA sequencing. First, DNA was amplified by poly-
merase chain reaction (PCR). PCR were carried out in
25 ul volumes containing 20 ng genomic DNA, 0.4 mM
primers, 50 mM KCL, 10 mM Tris/HCl (pH 8.3),
0.025% Tween 20, 0.025 mg/ml BSA, 1.5 mM magne-
sium chloride, 0.4 mM dNTP and 1 U Taq polymerase
with the following oligonucleotide primers: forward
5’-ACCTGAGCCCACGAGACTTT-3’; reverse 5’-
TCGAGCCAGAGCTGGAATAT-3’. After an initial
denaturation step for 5 min at 94°C, 35 cycles of dena-
turing at 94°C for 30 s, annealing at 55°C for 30 s and
extension of 72°C for 30 s were performed, followed by
a final extension step of 72°C for 5 min. After it had
been amplified, the 312 bp PCR products was subjected
to direct sequencing on an ABI 3700 automated DNA
sequencer using a Dye Terminator Cycle sequencing kit
(Applied Biosystems, Foster City, CA).
Statistical analysis
The differences in genotype distributions between
patients and controls and the Hardy-Weinberg equili-
brium (HWE) of each marker were analyzed using a
chi-square test. Differences in age and age of onset
between three groups were calculated with t-test. Allelic
and genotypic frequency distributions were compared
between groups by chi-square tests for independence.
The univariate and multivariate logistic regression ana-
lyses were performed to evaluate the unique contribu-
tion of identified risk factors in the prediction of suicide
behaviors. Possible interactions between genetic variants
and other risk factors were also investigated using logis-
tic regression analyses. Odds ratio (OR) values and 95%
confidence intervals (CI) were calculated. The results
were considered nominally significant at the level of p <
0.05. The SPSS package (version 13.0 for Windows;
SPSS, Chicago, Illinois) was used for statistical analyses.
Results
Clinical characteristics of patients
The demographic and clinical characteristics of the
patients are presented in Table 1. The study population
consisted of 215 MDD+suicide (mean age ± SD, 33.4 ±
11.9 years) and 215 matched MDD-suicide (mean age ±
SD, 33.6 ± 10.8 years). For MDD+suicide group, one
hundred and seventy-one patients (79.5%) suicided by
drug overdose, hanging, drowning and 44 patients
(20.5%) suicided by violent methods such as several
deep cuts. No statistically significant differences were
observed between the MDD+suicide and MDD-suicide
groups for age, age at onset, course of disease or HDRS
scores.
Genotypes and allele frequencies in the TPH2
rs7305115 polymorphisms
A total of 430 unrelated, major depression patients with
and without suicide behaviors were genotyped for the
TPH2 rs7305115 polymorphisms. The distributions of
both TPH2 polymorphisms in MDD+suicide and MDD-
suicide were in agreement with the Hardy-Weinberg
equilibrium (HWE) applying the HWSIM computer pro-
gram http://krunch.med.yale.edu/hwsim. The distribu-
tions of genotypes for TPH2 rs7305115 polymorphisms
did not deviate from HWE in MDD with or without sui-
cide groups (Table 2). Homozygous genotypes were
identified by the presence of GG and AA, but the AG
for heterozygous genotype (Figure 1). In the total
Table 1 Demographic Characteristics of the MDD patients
with suicide and MDD patients without suicide
MDD+suicide MDD-suicide p value
Sex (males/females) 92/123 92/123
Age
(years, mean ± SD)
15 ~ 75
(33.4 ± 11.9)
15 ~ 77
(33.6 ± 10.8)
0.721
Age of onset
(years, mean ± SD)
14 ~ 75
(28.4 ± 10.3)
15 ~ 76
(29.4 ± 10.7)
0.565
Course of disease
(years, mean ± SD)
2 weeks ~ 25 years
(3.43 ± 4.52)
2 weeks ~ 29 years
(3.39 ± 4.54)
0.935
HDRS scores
a 51.19 ± 10.61 49.87 ± 10.49 0.079
a HDRS, Hamilton depression rating scale for depression
Table 2 Distribution of genotypes and allele frequencies
of TPH2 rs7305115 polymorphism
MDD
+suicide
(n = 215)
MDD-
suicide
(n = 215)
P value
a OR
(95%CI)
Genotype (N, %) < 0.001 –
AA 31 (14.4%) 63 (29.3%)
AG 118
(54.9%)
108
(50.2%)
GG 66 (30.7%) 44 (20.5%)
Genotype (N, %) < 0.001 0.406
AA 31 (14.4%) 63 (29.3%) (0.251-
0.657)
AG+GG 184
(85.6%)
152
(70.7%)
Allele (N, %) < 0.001 0.603
A 180
(41.9%)
234
(54.4%)
(0.461-
0.790)
G 250
(58.1%)
196
(45.6%)
a MDD+suicide vs. MDD-suicide, Pearson chi-square test.
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MDD+suicide and MDD-suicide in genotypic (AG and
GG) frequencies for TPH2 rs7305115 polymorphisms.
But the distribution of AA genotype differed signifi-
cantly between MDD-suicidea n dM D D + s u i c i d eg r o u p s
(29.3% vs.14.4%, p < 0.001). Meanwhile, the distribution
of AA genotype was significantly lower than AG+GG
group in MDD+suicide groups (14.4% vs. 85.6%, p <
0.001). The allele distributions of both A and G was sig-
nificant differences between MDD+suicide and
MDD-suicide in our sample. The G-allele frequency in
MDD+suicide was higher than MDD-suicide (58.1%
vs.45.6%, p < 0.001), but the A-allele carrier indicated a
decreased trend in MDD with suicide behaviors by com-
pared with MDD-suicide group (41.9% vs.54.4%,
p < 0.001). We suggested that the presence of the A-
allele was a significant predictor for suicide behaviors
because of the low frequency of the AA genotype in
MDD+suicide group.
Genotypes of TPH2 rs7305115 polymorphism and
HDRS scores in MDD+suicide group
We determined the genotypes of TPH2 rs7305115 poly-
morphism and HDRS scores in MDD+suicide group
(Table 3). The TPH2 rs7305115 SNP was not associated
with HDRS scores in sum for MDD+suicide (p = 0.092).
But, we found that HDRS scores of cognitive
impairment and hopelessness were associated with
TPH2 rs7305115 genotypes among MDD+suicide (p =
0.035 and p = 0.032). The patients with AA genotype
indicated lower HDRS scores for cognitive impairment
(mean ± SD, 7.90 ± 3.97) and hopelessness (mean ± SD,
9.60 ± 2.12) factors than AG and GG groups in MDD
with suicide behaviors. This suggested that the TPH2
rs7305115 AA could be a significant protective predictor
for suicide behaviors.
Figure 1 Schematic representation of TPH2 rs7305115 SNP. Arrows represent homozygous genotypes GG (A), AA (B) and heterozygous
genotype AG (C) of TPH2 rs7305115 SNP investigated in this study.
Table 3 Genotypes of TPH2 rs7305115 polymorphism
and HDRS scores in MDD+suicide group (scores, mean ±
SD)
Genotype P
value
AA AG GG
Anxiety/
Somatization
l2.83 ± 4.03 l2.11 ± 3.72 l2.01 ± 3.83 0.113
Loss of weight 1.81 ± 0.54 1.78 ± 0.54 1.55 ± 0.48 0.832
Cognitive
impairment
7.90 ± 3.97 10.05 ± 4.23 10.93 ± 3.82 0.035
Diurnal change 1.76 ± 1.27 1.67 ± 1.26 1.45 ± 0.97 0.223
Slow movement 10.23 ± 2.41 9.15 ± 2.33 9.38 ± 2.75 0.468
Sleep disorders 5.61 ± 0.66 5.24 ± 0.71 5.60 ± 0.85 0.176
Hopelessness 9.60 ± 2.12 11.57 ± 1.80 11.29 ± 2.10 0.032
HDRS scores in sum 49.80 ±
l0.57
51.49 ±
l0.71
52.28 ±
l0.83
0.092
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To investigate the predictive power of AA genotype of
TPH2 rs7305115 polymorphisms, a univariate logistic
regression analysis was performed to examine the pre-
dictive effect of each factor on the risk for behaviors in
MDD patients (Table 4). The 36 potential risk factors
for MDD+suicide group were compared with those of
MDD-suicide group. Compared with the AG and GG
groups, the AA group (OR = 0.50, 95% CI = 0.31-0.82,
p < 0.001) were at lower risk for suicide attempts. The
TPH2 polymorphism emerged as a significant variable
that could reliably predict clinical suicide behaviors.
Significant risk factors were entered into a forward
selection multivariate logistic regression analysis. The
involvement of sixteen factors in MDD+suicide was ana-
lyzed using multiple logistic regression analysis. Using
this model, the degree of involvement of each factor for
suicide patients could be estimated (Table 5). On multi-
variate analysis, the final model indicated that TPH2
rs7305115 AA (OR 0.33, 95% CI 0.22-0.99, P < 0.001),
family history of suicide (OR 2.98, 95% CI 1.17-5.04, P <
0.001), negative life events half year ago (OR 6.64, 95%
CI 2.48-11.04, P < 0.001) and hopelessness (OR 7.68,
95% CI 5.79-13.74, P < 0.001) were significantly asso-
ciated with the suicide behaviors in MDD patients. The
TPH2 rs7305115A remained a significant protective pre-
dictor of suicide behaviors.
Further, we examined the interactions between TPH2
genotypes and the potential three factors on the risk for
MDD+suicide group (Table 6). The results indicated
that family history of suicide, negative life events half
year ago and hopelessness were significantly associated
with TPH2 genotypes in MDD+suicide patients (p =
0.006, p = 0.005, and p = 0.002, respectively).
Discussion
Suicide receives increasing attention worldwide, with
many countries developing national strategies for pre-
vention. Rates of suicide vary greatly between countries,
with the greatest burdens in developing countries [22].
Most people who die by suicide have psychiatric disor-
ders, notably mood, substance-related, anxiety, psycho-
tic, and personality disorders, with comorbidity being
common [23]. Risk for suicide may have genetic contri-
butions, however, specific genes or relevant DNA
sequence variations have not yet been identified [24].
Therefore, it is a major research challenge to clarify the
relative heritability of the risk for suicide, in particular,
separately from the heritability of disorders or traits that
are strongly associated with suicidal risk [25].
The rate-limiting enzyme of serotonin biosynthesis,
TPH2, is one of the most promising candidate genes for
psychiatric disorders [26]. In the present study, we
Table 4 Results from univariate logistic regression
analysis i.e., OR, 95% CI, Wald statistic, and probability
values for predictor variables of MDD suicide behaviors
Variables OR 95% CI Wald P value
Education under middle school 2.39 1.62-3.52 19.705 0.000
Married 0.20 0.12-0.32 46.600 0.000
Age of onset (= ≥ 35 years) 0.79 0.54-1.17 1.407 0.236
Short course of diseases (= ≤ 1 year) 0.83 0.57-1.21 0.943 0.332
Employed 0.67 0.45-1.00 3.809 0.051
Family history of Mental illness 0.94 0.64-1.39 0.086 0.769
Onset abruptly or subacute 1.13 0.76-1.68 0.366 0.545
Predisposing factors 1.15 0.78-1.72 0.500 0.479
Unhappy childhood 1.12 0.70-1.80 0.233 0.650
Family history of suicide 2.58 1.47-4.54 11.328 0.001
Physical disease 1.15 0.69-1.93 0.279 0.597
Monthly income (= < $40) 2.02 1.37-2.99 7.892 0.005
Smoking 1.64 1.02-2.65 4.164 0.041
Drinking 1.64 1.07-2.53 5.178 0.023
Introversion 1.90 1.25-2.87 9.155 0.002
Economic pressure 2.58 1.64-4.05 17.434 0.000
Unhappy a month ago 0.96 0.65-1.42 0.040 0.841
Unhappy a year ago 1.14 0.76-1.72 0.397 0.529
Unhappy after a year 0.87 0.60-1.31 0.362 0.547
Friend suicide two weeks ago 1.11 0.46-2.66 0.050 0.823
Friend suicide a year ago 1.22 0.60-2.49 0.295 0.587
Negative life events half year ago 5.74 3.28-
10.04
43.365 0.000
Family emotional support needed 0.43 0.26-0.72 10.587 0.001
Family emotional support gained 1.06 0.72-1.55 0.086 0.769
Friends’ emotional support needed 0.38 0.24-0.60 16.025 0.000
Friends’ emotional support gained 1.06 0.72-1.55 0.084 0.772
Depression (HDRS = ≥ 35)
a 1.58 1.07-2.34 5.227 0.020
Hopelessness (HDRS = ≥ 6)
a 7.68 4.99-
11.83
93.755 0.000
Anxiety/Somatization(HDRS = > 7)
a 0.84 0.56-1.27 0.706 0.401
Loss of weight in a week(= 0.5 kg) 0.93 0.64-1.36 0.149 0.699
Cognitive impairment(HDRS = > 12)
a 1.17 0.77-1.78 0.553 0.457
Diurnal change (HDRS = ≥ 1)
a 1.12 0.76-1.66 0.350 0.554
Slow movement (HDRS = ≥ 8)
a 1.12 1.77-4.64 0.340 0.560
Sleep disorders (HDRS = ≥ 2)
a 3.28 2.20-4.88 35.128 0.000
Anxiety (HAMA = ≥ 21)
b 4.12 2.54-6.68 35.622 0.000
TPH2 rs7305115 AA 0.50 0.31-0.82 13.941 0.000
a HDRS, Hamilton depression rating scale for depression;
b HAMA, Hamilton anxiety scale for anxiety
Table 5 Results from multivariate logistic regression
analysis for predictor variables of MDD+suicide group
Variables OR 95% CI Wald P value
TPH2 rs7305115 AA 0.33 0.22-0.99 12.861 0.000
Family history of suicide 2.98 1.17-5.04 10.228 0.001
Negative life events half year ago 6.64 2.48-11.04 41.145 0.000
Hopelessness (HDRS > = 6)
a 7.68 5.79-13.74 90.235 0.000
a HDRS, Hamilton depression rating scale for depression
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suicide attempters, and compared them to non-suicidal
depressed patients. We also investigated the association
of polymorphisms with the life environment factors
among suicide patients. The issue of association of TPH2
SNPs with suicide-related behavior is a complex and con-
troversial one. Several studies have indicated possible
associations between various TPH2 polymorphisms and
major depression, suicidal behavior [12,27]. In contrast,
other studies failed to find associations between TPH2
polymorphisms and suicidality [28,29]. Nevertheless, we
f o u n da na s s o c i a t i o no fs u i c i dal behavior with the TPH2
rs7305115 SNP in the present study. Our data shows that
MDD+suicide patients have low frequencies of the
rs7305115 A-allele and AA genotypes (OR = 0.50).
Studies indicated that a history of suicide attempt, a
psychiatric condition such as ongoing major depression,
alcohol or other substance use disorder, hopelessness,
separation or loss, anger, and suicidal ideation have
been implicated as predictors of suicidal behaviors
[30,31]. The MDD patients with greater levels of hope-
lessness also were prone to the multiple suicide attempts
[32]. Our findings indicated that cognitive impairment
and hopelessness were associated with TPH2 rs7305115
SNP among MDD+suicide patients.
The multivariate analysis indicated that four factors
(TPH2, family history of suicide, negative life events half
year ago and hopelessness) were significantly associated
with the suicide behaviors in MDD patients. The TPH2
rs7305115 AA remained a significant protective predic-
tor of suicide behaviors (OR = 0.33). The results sug-
gested that A®G mutation carriers of TPH2 rs7305115
SNP could be a higher risk of suicide attempts than AA
homozygous genotype carriers in MDD patients. To
identify the functional locus, it will be important to clo-
sely evaluate the significance of sequence variants in
coding regions that could alter gene expression at the
DNA or RNA levels.
Limitations
A number of limitations may be relevant to these studies.
First, we only paid attention on a SNP maker of the TPH2
gene in the current study. More TPH2 marker will be
examined for MDD patients with suicide behaviors in the
future study. Further, we had no the detail mechanistic
explanation regarding the role of serotonin functioning in
depression for TPH2 SNP. Further study is needed to elu-
cidate its mechanism. Understanding why the vulnerability
to suicide differs among MDD patients could assist in
improved screening of high risk patients and treatment.
Conclusions
In case-control association studies, our findings sug-
gested that the rs7305115 SNP in the TPH2 gene could
be a marker for the genetic susceptibility to suicide-
related traits in Chinese. The TPH SNP might influence
suicide-related traits in behaviorally extreme populations
and included an independent high risk clinical sample,
suicide attempters. We suggested that TPH2 gene could
regulate serotonergic system and contribute to the vul-
nerability to suicidal behavior.
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